[18F]-FDG PET/CT 在肛管鳞状细胞癌初始分期中的应用:前瞻性多中心登记研究结果
该前瞻性多中心登记研究纳入813例拟诊II-IV期肛管鳞状细胞癌患者,比较常规检查与PET分期的差异及其与生存的关系。PET使28.2%患者分期升高、15.8%分期降低,并为86.2%常规检查分期不明确者确定具体分期。PET分期可预测总生存和无进展生存,作者据此建议对临床II期及以上肛管鳞状细胞癌患者常规行PET分期。
要点
- PET使531例中150例(28.2%)分期升高、84例(15.8%)分期降低。
- PET为232例常规检查分期不明确者中的200例(86.2%)确定具体分期。
- PET分期与OS和PFS相关,PET IV期预示OS显著较差(P=0.005)。
核心结论
- 在拟诊II-IV期肛管鳞状细胞癌患者中,PET分期与常规检查分期差异可达44%。
- PET能为大多数常规检查分期不明确的患者确定具体分期。
- PET所得分期可预测无进展生存和总生存;作者认为因预后判断更优,应对临床II期及以上肛管鳞状细胞癌患者常规使用PET分期。
研究设计与样本
- 前瞻性多中心登记研究,纳入拟诊常规检查II-IV期肛管鳞状细胞癌或某分期检查结果不明确的患者,共813例。
- 记录并按美国癌症联合委员会(AJCC)第7版比较常规检查与PET分期,并与总生存比较。
- 对其中1家参与机构的136例患者,按AJCC第7-9版比较常规检查与PET分期,并与无进展生存和总生存比较。
主要发现
- 813例患者中,531例有可比较的分期信息:PET使150例(28.2%)分期升高,84例(15.8%)分期降低。
- 232例常规检查分期不明确者中,PET为200例(86.2%)确定了具体分期。
- PET IV期预示总生存显著较差(P=0.005)。
- 136例按AJCC第7-9版分期的患者中,常规检查分期I-IV期对总生存无预测价值(P分别为0.684、0.329、0.083),对无进展生存亦无预测价值(P分别为0.622、0.606、0.115)。
- 该136例中,PET分期I-IV期与总生存相关(P分别为0.037、0.003、0.003),与无进展生存相关(P分别为0.004、<0.001、<0.001),第9版对II期和III期的无进展生存区分最佳。
关键数值与推荐
- PET使531例中150例(28.2%)分期升高、84例(15.8%)分期降低。
- PET为232例常规检查分期不明确者中的200例(86.2%)确定具体分期。
- PET IV期与总生存显著较差相关(P=0.005)。
- 136例中,常规检查AJCC第7-9版分期I-IV期对总生存无预测价值(P=0.684、0.329、0.083),对无进展生存亦无预测价值(P=0.622、0.606、0.115)。
- 136例中,PET AJCC第7-9版分期I-IV期与总生存相关(P=0.037、0.003、0.003),与无进展生存相关(P=0.004、<0.001、<0.001)。
临床怎么用
- 作者认为,因PET分期预后判断更优,应对临床II期及以上肛管鳞状细胞癌患者常规使用PET进行分期。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
In patients with squamous cell carcinoma of the anal canal (ACC), disease stage influences treatment plans and determines prognosis. Our purpose was to determine the impact of PET on the initial staging of patients with presumed stages II-IV ACC and to assess the association of disease stage per conventional workup (CW) and PET imaging to patient outcomes. Methods: In this multicenter registry, patients with CW stages II-IV ACC or equivocal findings for a specific stage were included. Demographic data and stage according to the American Joint Committee on Cancer (AJCC) version 7 as determined by CW and PET were recorded and compared with overall survival (OS). For patients from 1 of the participating institutions, CW and PET stage according to AJCC versions 7-9 were compared with progression-free survival (PFS) and OS. Results: There were 813 patients included. PET upstaged 150 of 531 patients (28.2%) and downstaged 84 of 531 patients (15.8%) and assigned a specific stage to 200 of 232 patients (86.2%) with equivocal findings on CW. Stage IV on PET was predictive of significantly poorer OS (P = 0.005). For the 136 patients with staging according to AJCC versions 7-9, CW stages I-IV per versions 7-9 were not predictive of OS (P = 0.684, 0.329, and 0.083, respectively) or PFS (P = 0.622, 0.606, and 0.115, respectively). However, PET stages I-IV per versions 7-9 were associated with OS (P = 0.037, 0.003, 0.003, respectively) and PFS (P = 0.004, <0.001, <0.001, respectively), with version 9 best discriminating PFS for stages II and III. Conclusion: In patients with presumed stages II-IV ACC, PET stage differs in up to 44% from CW. PET assigns a specific stage in most patients with equivocal staging on CW. The PET-derived stage was predictive of PFS and OS. Because of its superior prognostication, PET should be used routinely to stage patients with ACC clinical stage II or above.
引用
- Metser U, Lukovic J, Mesci A, et al. [18F]-FDG PET/CT in the Initial Staging of Squamous Cell Cancer of the Anal Canal: Results of a Prospective Multicenter Registry. J Nucl Med. 2025. PMID: 40049747. doi:10.2967/jnumed.124.269289
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。